Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details a specific transaction event where directors acquired shares through the GSK ShareReward Plan.
Management Commentary and Unusual Items
On March 10, 2015, eleven Directors and PDMRs acquired GSK Ordinary Shares at a price of 1,547.58 pence per share. The acquisitions were made through the ShareReward Plan, consisting of:
- 8 shares under the personal contribution element.
- 8 shares under the matching element (GSK contribution).
The participating individuals included Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
Investor Verification Checklist
- Verify the share price of 1,547.58 pence against market data for March 10, 2015.
- Confirm the total number of shares acquired by each listed director (16 shares per individual).
- Review the terms of the GSK ShareReward Plan to understand the matching contribution structure.
- Check subsequent filings for any changes in director shareholdings or plan participation.